Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome

Stefano Palomba, Tiziana Russo, Francesco Orio, Angela Falbo, Francesco Manguso, Teresa Cascella, Achille Tolino, Enrico Carmina, Annamaria Colao, Fulvio Zullo

Research output: Contribution to journalArticle

Abstract

Background: Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods: Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whilst under metformin treatment (PCOS group) and in controls, uterine, sub-endometrial and endometrial blood flow, and endometrial thickness and pattern were evaluated using serial ultrasonographic assessments. Results: Before treatment, uterine, sub-endometrial and endometrial blood flows were significantly lower in patients with PCOS than in the control group. All indexes of uterine vascularization were significantly improved in the PCOS group with metformin treatment and were not different from the controls. Nor was any difference in endometrial thickness and pattern detected between PCOS and control groups. After grouping the data of PCOS patients who ovulated under metformin for cycles with favourable/unfavourable reproductive outcome, no difference in any parameter was observed. Conclusions: Metformin improves all surrogate markers of endometrial receptivity in PCOS patients, without difference between patients who had favourable or unfavourable reproductive outcome.

Original languageEnglish
Pages (from-to)457-465
Number of pages9
JournalHuman Reproduction
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Polycystic Ovary Syndrome
Metformin
Control Groups
Spontaneous Abortion
Pregnancy Rate
Therapeutics
Ovulation
Fertility
Body Mass Index
Biomarkers

Keywords

  • Anovulation
  • Endometrium
  • Metformin
  • PCOS
  • Ultrasound

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Palomba, S., Russo, T., Orio, F., Falbo, A., Manguso, F., Cascella, T., ... Zullo, F. (2006). Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Human Reproduction, 21(2), 457-465. https://doi.org/10.1093/humrep/dei351

Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. / Palomba, Stefano; Russo, Tiziana; Orio, Francesco; Falbo, Angela; Manguso, Francesco; Cascella, Teresa; Tolino, Achille; Carmina, Enrico; Colao, Annamaria; Zullo, Fulvio.

In: Human Reproduction, Vol. 21, No. 2, 02.2006, p. 457-465.

Research output: Contribution to journalArticle

Palomba, S, Russo, T, Orio, F, Falbo, A, Manguso, F, Cascella, T, Tolino, A, Carmina, E, Colao, A & Zullo, F 2006, 'Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome', Human Reproduction, vol. 21, no. 2, pp. 457-465. https://doi.org/10.1093/humrep/dei351
Palomba, Stefano ; Russo, Tiziana ; Orio, Francesco ; Falbo, Angela ; Manguso, Francesco ; Cascella, Teresa ; Tolino, Achille ; Carmina, Enrico ; Colao, Annamaria ; Zullo, Fulvio. / Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. In: Human Reproduction. 2006 ; Vol. 21, No. 2. pp. 457-465.
@article{0fed394ca0ba47328d00663853762d94,
title = "Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome",
abstract = "Background: Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods: Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whilst under metformin treatment (PCOS group) and in controls, uterine, sub-endometrial and endometrial blood flow, and endometrial thickness and pattern were evaluated using serial ultrasonographic assessments. Results: Before treatment, uterine, sub-endometrial and endometrial blood flows were significantly lower in patients with PCOS than in the control group. All indexes of uterine vascularization were significantly improved in the PCOS group with metformin treatment and were not different from the controls. Nor was any difference in endometrial thickness and pattern detected between PCOS and control groups. After grouping the data of PCOS patients who ovulated under metformin for cycles with favourable/unfavourable reproductive outcome, no difference in any parameter was observed. Conclusions: Metformin improves all surrogate markers of endometrial receptivity in PCOS patients, without difference between patients who had favourable or unfavourable reproductive outcome.",
keywords = "Anovulation, Endometrium, Metformin, PCOS, Ultrasound",
author = "Stefano Palomba and Tiziana Russo and Francesco Orio and Angela Falbo and Francesco Manguso and Teresa Cascella and Achille Tolino and Enrico Carmina and Annamaria Colao and Fulvio Zullo",
year = "2006",
month = "2",
doi = "10.1093/humrep/dei351",
language = "English",
volume = "21",
pages = "457--465",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome

AU - Palomba, Stefano

AU - Russo, Tiziana

AU - Orio, Francesco

AU - Falbo, Angela

AU - Manguso, Francesco

AU - Cascella, Teresa

AU - Tolino, Achille

AU - Carmina, Enrico

AU - Colao, Annamaria

AU - Zullo, Fulvio

PY - 2006/2

Y1 - 2006/2

N2 - Background: Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods: Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whilst under metformin treatment (PCOS group) and in controls, uterine, sub-endometrial and endometrial blood flow, and endometrial thickness and pattern were evaluated using serial ultrasonographic assessments. Results: Before treatment, uterine, sub-endometrial and endometrial blood flows were significantly lower in patients with PCOS than in the control group. All indexes of uterine vascularization were significantly improved in the PCOS group with metformin treatment and were not different from the controls. Nor was any difference in endometrial thickness and pattern detected between PCOS and control groups. After grouping the data of PCOS patients who ovulated under metformin for cycles with favourable/unfavourable reproductive outcome, no difference in any parameter was observed. Conclusions: Metformin improves all surrogate markers of endometrial receptivity in PCOS patients, without difference between patients who had favourable or unfavourable reproductive outcome.

AB - Background: Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods: Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whilst under metformin treatment (PCOS group) and in controls, uterine, sub-endometrial and endometrial blood flow, and endometrial thickness and pattern were evaluated using serial ultrasonographic assessments. Results: Before treatment, uterine, sub-endometrial and endometrial blood flows were significantly lower in patients with PCOS than in the control group. All indexes of uterine vascularization were significantly improved in the PCOS group with metformin treatment and were not different from the controls. Nor was any difference in endometrial thickness and pattern detected between PCOS and control groups. After grouping the data of PCOS patients who ovulated under metformin for cycles with favourable/unfavourable reproductive outcome, no difference in any parameter was observed. Conclusions: Metformin improves all surrogate markers of endometrial receptivity in PCOS patients, without difference between patients who had favourable or unfavourable reproductive outcome.

KW - Anovulation

KW - Endometrium

KW - Metformin

KW - PCOS

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=31544442962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544442962&partnerID=8YFLogxK

U2 - 10.1093/humrep/dei351

DO - 10.1093/humrep/dei351

M3 - Article

C2 - 16253975

AN - SCOPUS:31544442962

VL - 21

SP - 457

EP - 465

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 2

ER -